NICE has assessed the procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) to help the NHS decide whether to use these products.
Procalcitonin is released into the bloodstream when there is a bacterial infection in the body and high levels can show that a person has a serious bacterial infection. Procalcitonin tests measure the amount of procalcitonin in the blood, and the results can help doctors to diagnose bacterial infection and decide about starting or stopping antibiotic treatment.
There was not enough evidence to recommend that these tests are used in the NHS. But NICE has recommended further research and data collection to show the impact of adding procalcitonin testing to standard clinical practice in the NHS.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.